Total Funding
22
Total FundingSeed raised
Growth Score
pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
PxRadia develops a humanized monoclonal antibody 2A2 for mitigating radiation toxicity and preventing cell death.
About the Company
PxRadia was formed in 2010 by Dr. Charles Morgan, a founder of multiple companies and a pioneer in monoclonal antibody development, with an exclusive license from Memorial Sloan-Kettering Cancer Center to commercialize the breakthrough research of Dr. Richard N. Kolesnick on the role of ceramide, a lipid, in cell signaling and cell death.
